Parenteral Impex Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 28-12-2024
- Paid Up Capital ₹ 0.50 M
as on 28-12-2024
- Company Age 18 Year, 30 Days
- Last Filing with ROC 31 Mar 2021
- Revenue %
(FY 2021)
- Ebitda
- Net Worth
- Total Assets 0.16%
(FY 2021)
About Parenteral Impex
The Corporate was formerly known as Aaditya Drugs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Gupta, Manohar Gupta, and Govind Garg serve as directors at the Company.
- CIN/LLPIN
U24239MH2006PLC166419
- Company No.
166419
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2006
- Date of AGM
19 Jul 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Parenteral Impex?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Gupta  | Director | 24-Apr-2019 | Current |
| Manohar Gupta | Director | 21-Dec-2006 | Current |
| Govind Garg | Director | 25-Aug-2007 | Current |
Financial Performance of Parenteral Impex.
Parenteral Impex Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Parenteral Impex?
In 2019, Parenteral Impex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Infutec Healthcare LimitedActive 19 years 4 monthsVinod Gupta, Manohar Gupta and 1 more are mutual person
Parenteral Biotech LimitedActive 29 years 1 monthVinod Gupta, Manohar Gupta and 1 more are mutual person
Pdpl Holdings Private LimitedActive 18 years 10 monthsVinod Gupta and Manohar Gupta are mutual person
- Pdpl Securities Private LimitedActive 18 years 10 months
Vinod Gupta, Manohar Gupta and 1 more are mutual person
- Infutec Healthcare (India) LimitedActive 9 years 9 months
Vinod Gupta, Manohar Gupta and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Parenteral Impex?
Unlock and access historical data on people associated with Parenteral Impex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parenteral Impex, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parenteral Impex's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
